There is evidence that the incretin response is blunted in people with obesity in the absence of underlying T2D, implying therapeutic potential in this often difficult-to-treat group.39 As weight loss outcomes in trials involving people with T2D are consistently promising, further clinical trials have investigated some drugs in this class to support weight loss in people without T2D. Here, GCG is linked to type 2 diabetes mellitus.